💸 The Tape

Now that Trulieve is on the NYSE, Curaleaf is preparing to follow, and the entire MSO landscape is repositioning for a post-Schedule III world, an uncomfortable question is starting to surface in boardrooms and investor calls: who has international exposure — and who doesn't?

The answer increasingly separates the companies that could become global cannabis platforms from those that remain domestic operators trading at domestic multiples. And it raises a provocative hypothetical: does it make strategic sense for Trulieve, Green Thumb Industries, or Verano to pursue some kind of partnership, joint venture, or merger with Tilray Brands to close the European gap — and challenge the international footprint Curaleaf has been quietly assembling for years?

The logic is seductive on the surface. The complications, as always, are in the details.

The Curaleaf Benchmark

Curaleaf has built what no other U.S.-origin cannabis company can currently match: a genuine transatlantic operation. The full acquisition of Four 20 Pharma in Germany, the Lyphe Group clinic and pharmacy platform in the UK, cultivation in Portugal, distribution across multiple European countries, and a medical ecosystem spanning clinical care, dispensing, and pharmaceutical distribution — it's a vertically integrated international platform that took years and hundreds of millions of dollars to construct.

For the other top-tier MSOs — Trulieve with its 206 medical dispensaries and dominant Florida position, GTI with $300 million quarterly revenue and the industry's strongest balance sheet, and Verano with 162 dispensaries across 13 states — the international column on their strategic roadmaps is essentially blank. They are domestic powerhouses with zero European infrastructure.

That's a problem if cannabis evolves into a global industry. And everything about rescheduling, DEA registration, and the normalization trajectory suggests it will.

What Tilray Brings

On paper, Tilray offers exactly what the top MSOs lack: established European medical cannabis operations, international distribution networks, and regulatory expertise across multiple jurisdictions.

The company's Tilray Medical platform operates in more than 20 markets worldwide and has served hundreds of thousands of patients globally. The recent acquisition of Lyphe Group in the UK — with 150,000 units dispensed and 16,000 patients treated — gives Tilray its first fully vertically integrated medical platform combining clinical services, patient access, and pharmaceutical distribution. CC Pharma, Tilray's German pharmaceutical distribution subsidiary, provides established logistics and purchasing infrastructure across Europe's largest medical cannabis market.

Tilray also holds cultivation and processing capabilities in Canada and Portugal, EU GMP compliance expertise, and relationships with regulators across the continent. For a U.S. MSO looking to enter Europe without spending five years building from scratch, Tilray's medical infrastructure is genuinely valuable.

The Problem: Everything Else

Here's where the thesis starts to strain. Tilray isn't just a European medical cannabis company. It's a sprawling, diversified consumer platform with significant exposure to businesses that would create more questions than answers in a potential tie-up with a focused U.S. MSO.

Start with alcohol. Tilray's beverage portfolio now includes BrewDog — acquired with ambitious plans to rebuild it toward its prior $1 billion valuation — along with SweetWater Brewing, Montauk Brewing, Alpine Beer, and a collection of American craft brands. CEO Irwin Simon has positioned Tilray as a "global lifestyle and consumer packaged goods company" straddling cannabis, beverages, and wellness.

For a company like Trulieve, GTI, or Verano — each of which has built its identity and investor narrative around pure-play cannabis operations — absorbing a beer portfolio, a chain of British brewpubs, and a functional beverage business would be strategically incoherent. Investors in U.S. MSOs are buying cannabis exposure, not craft beer distribution. The beverage assets would likely need to be divested or separated in any combination, adding complexity, cost, and execution risk to a transaction that's supposed to simplify international market access.

Then there's the Canadian cannabis business. Tilray remains one of Canada's largest licensed producers, but the Canadian recreational market has been a margin grinder for years. Price compression, oversupply, and intense competition have made Canadian cannabis operations a drag on profitability for virtually every LP. While Tilray has managed better than most — maintaining market share through brands like Broken Coast, Good Supply, and REVEL — the Canadian recreational business is not the asset that would attract a U.S. MSO partner. It's the baggage that comes with the European prize.

The $180 million ATM equity program Tilray filed to fund its beverage expansion only compounds the concern. Dilution has been a persistent overhang on Tilray's stock, and any acquiring MSO would inherit that capital structure dynamic.

Could a Partial Deal Work?

The more realistic scenario isn't a full merger — it's a targeted transaction involving Tilray's European medical assets specifically. A joint venture, asset carve-out, or strategic partnership focused on Tilray Medical, CC Pharma, and the Lyphe platform could give a U.S. MSO instant European infrastructure without absorbing the beverage portfolio or Canadian recreational exposure.

GTI might be the most logical candidate for such a structure. With $344.5 million in cash, a net cash balance sheet, and the operational discipline to integrate selectively, GTI could pursue a European medical partnership without overextending. The company has already demonstrated appetite for strategic capital deployment through its $200 million cumulative share buyback — redirecting a portion of that firepower toward international assets could diversify revenue at a time when domestic growth is moderating.

Trulieve, has the visibility and credibility to pursue international expansion — but its near-term focus is clearly on maximizing the domestic medical business and preparing for potential reconsolidation of its adult-use operations. Adding European complexity on top of the deconsolidation structure might be one move too many.

Verano, with its $195 million term loan and active domestic expansion, is more likely focused on balance sheet optimization than international M&A.

The Honest Assessment

The strategic case for a top-tier MSO acquiring Tilray's European medical assets is real. The case for acquiring all of Tilray — including its beer brands, Canadian operations, and diversified consumer platform — is much harder to make.

Curaleaf didn't build its European presence by acquiring a conglomerate. It bought targeted, focused assets — Four 20 Pharma, Lyphe, cultivation in Portugal — and integrated them into a coherent international medical ecosystem. That's the playbook that works.

A Tilray tie-up would give a U.S. MSO the European exposure it needs. It would also give it a brewery chain, a craft beer distribution network, and a Canadian recreational business it doesn't want. The question is whether the prize is worth the price of untangling everything around it.

The European cannabis opportunity is real and growing. The path to capturing it doesn't necessarily run through Tilray's entire portfolio — but it almost certainly runs through pieces of it. The MSO that figures out how to extract the medical infrastructure without absorbing the rest may find the most efficient route to challenging Curaleaf's international lead.

Sometimes the best acquisition isn't a company. It's a carve-out.

📈 Dog Walkers

$VFF ( ▼ 15.39% ) Raises Some Dough

Village Farms International wasn't looking to raise money. But when the right investors came knocking, management opened the door.

The company announced a registered direct offering of 7.5 million common shares expected to generate approximately $15 million in gross proceeds, placed through A.G.P./Alliance Global Partners as sole placement agent. What makes this raise notable isn't the size — it's the context. CEO Michael DeGiglio emphasized that the offering followed meetings with two new institutional capital partners that "created considerable interest in a direct investment that was not previously being contemplated."

In other words: Village Farms didn't need the cash. It took it because the investors were too good to turn away.

The company closed Q1 2026 with $55 million in cash, posted 27% revenue growth, 118% adjusted EBITDA growth, and has been generating positive operating cash flow. DeGiglio was explicit that the balance sheet "does not require a capital infusion" but that the opportunity to "enhance the strength of our cap table" with high-caliber U.S. institutional investors was too compelling to pass up.

That framing matters. When institutional capital begins entering cannabis — particularly into a company operating the world's largest EU-GMP certified cannabis facility with record international export sales and leadership in the Canadian market — it signals something broader about how the investment community is reassessing the sector under Schedule III.

Net proceeds will be used for working capital and general corporate purposes, and Village Farms continues to expect it will grow its cash balance through positive operating cash flow for the remainder of 2026. Upon closing, expected on or about June 8, the company will have approximately 121.8 million shares outstanding.

DeGiglio called the raise "a tremendous endorsement of Village Farms." Given the company's trajectory, it's hard to argue with that characterization.

$TCNNF ( ▲ 17.52% ) To Debut On NYSE This Week

The company announced that its subordinate voting shares have been approved for listing on the New York Stock Exchange, making it the first U.S. cannabis company to trade on a major American stock exchange. Shares begin trading under the symbol "TRLV" at market open on June 10, 2026.

CEO Kim Rivers called it "a major advancement for Trulieve and the industry," crediting President Trump's reclassification of medical marijuana to Schedule III for paving the way. The listing follows Trulieve's deconsolidation of its adult-use operations last week — a corporate restructuring that separated the medical business into a standalone, NYSE-eligible entity.

The consolidated medical-only Trulieve includes 206 medical marijuana dispensaries and 3.5 million square feet of DEA-registered production capacity. The company cited robust cash generation and meaningful growth catalysts ahead, including expansion in Georgia and Texas.

Shares will continue trading on the CSE under "TRUL" and OTCQX under "TCNNF" through market close on June 9. Current shareholders don't need to take any action.

The significance cannot be overstated. After years of being confined to Canadian exchanges and OTC markets, a U.S. cannabis operator is officially on the NYSE. The door is open — and every other MSO is watching.

🗞️ The News

📺 Trade To Black

Trulieve Becomes First Cannabis MSO Approved For NYSE | TDR Cannabis in 5

• Historic First: Trulieve becomes the first U.S. cannabis operator approved to trade on the NYSE under ticker "TRLV", marking the most significant capital markets milestone in the industry's history.

• Who's Next?: With Curaleaf's reverse stock split already in motion and Verano following suit, investors are asking whether Green Thumb, Cresco Labs, and other major MSOs will pursue similar uplisting strategies.

• The Deconsolidation Playbook: Trulieve's path — separating medical from adult-use operations to meet exchange requirements under Schedule III — could become the template other operators replicate to access senior exchanges.

• New Chapter: The listing opens the door to institutional participation, expanded analyst coverage, index inclusion, and improved liquidity — fundamentally changing how Wall Street can engage with U.S. cannabis for the first time.